Abstract LB-B33: Nonclinical safety evaluation of two distinct second generation variants of anti-CTLA4 monoclonal antibody, ipilimumab, in monkeysKaren Price, Michael J. Graziano, Rima Srour et al.|Molecular Cancer Therapeutics|2018Cited by 11
Opportunities and challenges for use of minipigs in nonclinical pharmaceutical development: Results of a follow-up IQ DruSafe surveyDavid O. Clarke, Thierry Flandre, Kaushik Datta et al.|Regulatory Toxicology and Pharmacology|2024Cited by 4